Hosted by the award-winning editorial staff of Ophthalmology Times®, EyePod podcasts feature the latest updates and resources most relevant to professionals across the eyecare industry. Two sponsored EyePod episodes are released each month exclusively on the Ophthalmology Times® website
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in part 4 of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in part 3 of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 2)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in the second part of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 1)
September 13th 2023In this podcast, Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease.
(Podcast) Confronting Demodex blepharitis: From rude awakening to FDA-approved solution
August 30th 2023In this podcast episode, Ophthalmology Times' co-chief medical editors Peter J. McDonnell, MD, and Neda Shamie, MD, delve into the clinical nuances of Demodex blepharitis. Through personal anecdotes, they stress its underrecognized gravity and discuss diagnostic cues like collarettes. The experts share their enthusiasm for improved treatments, echoing the transformative impact seen in dry eye care.
EyePod: Pickleball popularity and eye injuries on the rise
July 9th 2023In the sport, which is a hybrid of badminton, ping-pong and tennis, players use a plastic-perforated ball, slightly heavier than a whiffle ball, and wooden or composite paddles that are about twice the size of ping-pong paddles, with a high potential for eye injuries.
The importance of ocular health prior to cataract and refractive surgery
February 28th 2023Dr. Jai Parekh, a clinical associate professor of Ophthalmology/The New York Eye & Infirmary of the Mount Sinai School of Medicine and David Hutton, Managing Editor of Opthalmology Times discuss the importance of ocular health prior to cataract and refractive surgery, specifically with osmolarity testing.
Commercial real estate and your practice, part two with Colin Carr
May 21st 2022On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the Q&A with Ophthalmology Times® executive editor, David Hutton.
The changing landscape of gene therapy and standardized endpoints
February 23rd 2022In this episode of EyePod, Ora Clinical’s Keith Lane offers a brief overview of the current state of ophthalmology and its standardized endpoints. He also discusses some of the challenges that gene therapy has faced, particularly in relation to ophthalmology. He also offers his outlook for the future of gene therapy.
ROP: Treating and preventing blindness in preterm babies
October 18th 2021Retinopathy of prematurity expert C. Armitage Harper, III, MD, of the Austin Retina Associates in Austin, Texas, discusses his experience in treating ROP cases across the globe, and his mission to prevent pre-term blindness in infants.
Highlighting results from first FDA-reported study for treatment of presbyopia
September 27th 2021George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.